Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 May 2015: Trial started, NCT02455557
  2. 28 May 2015: Trial registered, NCT02455557

The trials

NCT02455557: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

State
Under way
Phase
Phase 2
People
66 taking part
Started
4 May 2015
Primary completion
23 Oct 2019
Arms
Treatment (SurVaxM, temozolomide)
Results
Posted on the registry
  1. 4 May 2015: Trial started
  2. 28 May 2015: Trial registered
  3. 1 Feb 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.